European regulators are recommending approval for Boehringer Ingelheim and Eli Lilly’s latest diabetes offering, shrugging off a manufacturing issue that spiked the drug’s FDA approval and putting the pair in line for third place in a new class of treatments.

…read more

Source: EU smiles on Lilly and Boehringer’s FDA-rejected diabetes drug


0 No comments